| 000 | 01740 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516184736.0 | ||
| 264 | 0 | _c20140730 | |
| 008 | 201407s 0 0 eng d | ||
| 022 | _a1365-2893 | ||
| 024 | 7 |
_a10.1111/jvh.12118 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMandorfer, M | |
| 245 | 0 | 0 |
_aRevisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels. _h[electronic resource] |
| 260 |
_bJournal of viral hepatitis _cJan 2014 |
||
| 300 |
_a33-41 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aDrug Therapy, Combination _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xcomplications |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdiagnosis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRecombinant Proteins _xtherapeutic use |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 |
_agamma-Glutamyltransferase _xblood |
| 700 | 1 | _aReiberger, T | |
| 700 | 1 | _aPayer, B A | |
| 700 | 1 | _aBreitenecker, F | |
| 700 | 1 | _aAichelburg, M C | |
| 700 | 1 | _aObermayer-Pietsch, B | |
| 700 | 1 | _aRieger, A | |
| 700 | 1 | _aPuoti, M | |
| 700 | 1 | _aZangerle, R | |
| 700 | 1 | _aTrauner, M | |
| 700 | 1 | _aPeck-Radosavljevic, M | |
| 773 | 0 |
_tJournal of viral hepatitis _gvol. 21 _gno. 1 _gp. 33-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jvh.12118 _zAvailable from publisher's website |
| 999 |
_c23359237 _d23359237 |
||